trending Market Intelligence /marketintelligence/en/news-insights/trending/wmhLM9qjeIyNVM5yfd25Zg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

China FDA accepts FibroGen's application for anemia treatment

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


China FDA accepts FibroGen's application for anemia treatment

The China Food and Drug Administration accepted FibroGen Inc.'s new drug application for roxadustat.

Roxadustat is indicated for treating anemia, a deficiency of red blood cells, in patients with dialysis-dependent chronic kidney disease, or CKD, and non-dialysis-dependent CKD.

The new drug application submission also triggered a $15 million milestone payment from AstraZeneca PLC payable to FibroGen under a deal between the two companies. FibroGen is co-developing roxadustat with AstraZeneca.

The application is based on the results of two phase 3 studies.